GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Beneish M-Score

ARAY (Accuray) Beneish M-Score : -2.35 (As of Dec. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Accuray Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Accuray's Beneish M-Score or its related term are showing as below:

ARAY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.3   Med: -2.67   Max: -1.75
Current: -2.35

During the past 13 years, the highest Beneish M-Score of Accuray was -1.75. The lowest was -3.30. And the median was -2.67.


Accuray Beneish M-Score Historical Data

The historical data trend for Accuray's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Beneish M-Score Chart

Accuray Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.51 -2.85 -2.30 -2.72 -2.38

Accuray Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -2.78 -2.50 -2.38 -2.35

Competitive Comparison of Accuray's Beneish M-Score

For the Medical Devices subindustry, Accuray's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accuray's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Accuray's Beneish M-Score falls into.



Accuray Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Accuray for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.228+0.528 * 1.1246+0.404 * 0.9185+0.892 * 0.9763+0.115 * 0.9008
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0124+4.679 * -0.015486-0.327 * 1.0131
=-2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $92.8 Mil.
Revenue was 101.545 + 134.289 + 101.132 + 107.238 = $444.2 Mil.
Gross Profit was 34.469 + 38.452 + 29.074 + 35.902 = $137.9 Mil.
Total Current Assets was $329.5 Mil.
Total Assets was $473.1 Mil.
Property, Plant and Equipment(Net PPE) was $58.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.1 Mil.
Selling, General, & Admin. Expense(SGA) was $93.9 Mil.
Total Current Liabilities was $201.8 Mil.
Long-Term Debt & Capital Lease Obligation was $194.2 Mil.
Net Income was -3.954 + 3.387 + -6.342 + -9.621 = $-16.5 Mil.
Non Operating Income was 1.775 + -0.063 + 1.548 + -1.857 = $1.4 Mil.
Cash Flow from Operations was -7.294 + 9.882 + -8.102 + -5.093 = $-10.6 Mil.
Total Receivables was $77.4 Mil.
Revenue was 103.892 + 118.292 + 118.06 + 114.76 = $455.0 Mil.
Gross Profit was 39.493 + 37.678 + 38.718 + 42.967 = $158.9 Mil.
Total Current Assets was $334.1 Mil.
Total Assets was $476.8 Mil.
Property, Plant and Equipment(Net PPE) was $49.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.6 Mil.
Selling, General, & Admin. Expense(SGA) was $95.0 Mil.
Total Current Liabilities was $201.4 Mil.
Long-Term Debt & Capital Lease Obligation was $192.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(92.756 / 444.204) / (77.37 / 455.004)
=0.208814 / 0.170042
=1.228

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(158.856 / 455.004) / (137.897 / 444.204)
=0.349131 / 0.310436
=1.1246

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (329.543 + 58.478) / 473.078) / (1 - (334.147 + 49.341) / 476.83)
=0.179795 / 0.195755
=0.9185

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=444.204 / 455.004
=0.9763

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.602 / (4.602 + 49.341)) / (6.118 / (6.118 + 58.478))
=0.085312 / 0.094712
=0.9008

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(93.92 / 444.204) / (95.029 / 455.004)
=0.211434 / 0.208853
=1.0124

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((194.244 + 201.806) / 473.078) / ((192.598 + 201.449) / 476.83)
=0.837177 / 0.826389
=1.0131

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.53 - 1.403 - -10.607) / 473.078
=-0.015486

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Accuray has a M-score of -2.35 suggests that the company is unlikely to be a manipulator.


Accuray Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Accuray's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joseph E Whitters director
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043